Dr. Agarwals Health Care Ltd (AGARWALEYE) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 544350 | NSE: AGARWALEYE | Hospital & Healthcare Services | Small Cap

Dr. Agarwals Health Share Price

499 -4.25 -0.84%
as on 05-Dec'25 14:26

Dr. Agarwals Health Care Ltd (AGARWALEYE) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 544350 | NSE: AGARWALEYE | Hospital & Healthcare Services | Small Cap

DeciZen - make an informed investing decision on Dr. Agarwals Health

Based on:

Overall Rating
Login to view analysis. Bole Toh

1. Quality


Login to view analysis.

2. Valuation


Login to view analysis.

3. Price Trend


Login to view analysis.

Dr. Agarwals Health Care stock performance -

Key Ratios
mw4me loader
P/E Ratio (CD):
138.78
Market Cap:
15,911.3 Cr.
52-wk low:
327.4
52-wk high:
567.8

Is Dr. Agarwals Health Care Ltd an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray of Dr. Agarwals Health: Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Dr. Agarwals Health Care Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 0%0%0%0%10.5%-1.1%24.3%21.5%17.8%14.3%-
Value Creation
Index
NANANANA-0.2-1.10.80.60.30.1-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 00005314716961,0181,3321,7111,877
Sales YoY Gr.-NANANANA-11.2%47.7%46.2%30.9%28.4%-
Adj EPS 0000-1.2-2.81.63.92.32.43.6
YoY Gr.-NANANANANANA148.7%-41.2%4.4%-
BVPS (₹) 000012.1910.326.447.658.861.1
Adj Net
Profit
0000-23.6-57.632.192.263.975.3115
Cash Flow from Ops. 000010399.2164233346360-
Debt/CF from Ops. 00001.61.91.81.51.10.7-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales NA26.4%35%28.4%
Adj EPS NANA15.1%4.4%
BVPSNA37.2%78.6%23.4%
Share Price - - - -

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
0000-9.5-26.616.221.96.54.76.1
Op. Profit
Mgn %
000023.316.626.126.727.226.627.2
Net Profit
Mgn %
0000-4.3-12.85.4105.766.1
Debt to
Equity
00000.711.40.60.30.10.1
Working Cap
Days
000001007665627468
Cash Conv.
Cycle
000001-16-12-7-324

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials - Dr. Agarwals Health Care Ltd.

Standalone Consolidated
TTM EPS (₹) 1.6 3.6
TTM Sales (₹ Cr.) 1,160 1,877
BVPS (₹.) 61.8 61.1
Reserves (₹ Cr.) 1,924 1,899
P/BV 8.14 8.24
PE 325.25 138.78
From the Market
52 Week Low / High (₹) 327.40 / 567.80
All Time Low / High (₹) 327.40 / 567.80
Market Cap (₹ Cr.) 15,911
Equity (₹ Cr.) 31.6
Face Value (₹) 1
Industry PE 90.5

Management X-Ray of Dr. Agarwals Health:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Dr. Agarwals Health - Consolidated Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Dr. Agarwals Health

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales5314716961,0181,3321,711
Operating Expenses 4073945147489701,260
Manufacturing Costs153142184290436558
Material Costs696084113137162
Employee Cost 112116140190243327
Other Costs 7477107155155213
Operating Profit 12477182270362451
Operating Profit Margin (%) 23.3%16.3%26.1%26.5%27.2%26.4%
Other Income 131422184957
Interest 54444976101115
Depreciation 939598128170231
Exceptional Items 00000-3
Profit Before Tax -11-485784141160
Tax 91014-204650
Profit After Tax -20-584310395110
PAT Margin (%) -3.7%-12.4%6.2%10.1%7.1%6.4%
Adjusted EPS (₹)-1.0-2.71.84.03.02.6
Dividend Payout Ratio (%)0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 2491842126281,3331,857
Share Capital 7778932
Reserves 2421772066201,3241,825
Minority Interest181421304060
Debt157178264310325157
Long Term Debt145168254306310157
Short Term Debt1210105150
Trade Payables647589101133153
Others Liabilities 2523234257018851,412
Total Liabilities 7407741,0121,7702,7163,640

Fixed Assets

Gross Block7388541,0821,7942,3993,397
Accumulated Depreciation188279381501653871
Net Fixed Assets 5515757011,2931,7462,526
CWIP 8112899118153
Investments 10034471264
Inventories332833365280
Trade Receivables5247577697124
Cash Equivalents 4465117149125258
Others Assets 50487683108234
Total Assets 7407741,0121,7702,7163,640

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity 10399164233346360
PBT -11-485784141160
Adjustment 139145138197233332
Changes in Working Capital -910-15-135-94
Tax Paid -16-7-16-35-32-37
Cash Flow From Investing Activity -80-37-155-509-914-750
Capex -201-33-70-157-228-320
Net Investments 00-87-348-693-284
Others 122-31-47-146
Cash Flow From Financing Activity -73-3735303553382
Net Proceeds from Shares 000301637280
Net Proceeds from Borrowing 3220000
Interest Paid -32-19-21-29-32-32
Dividend Paid -0-0-0-0-1-1
Others -45-405632-51135
Net Cash Flow -50254427-15-8

Finance Ratio

PARTICULARSMar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)-7.89-26.9521.7724.589.696.92
ROCE (%)10.53-1.0924.2621.5117.7714.32
Asset Turnover Ratio0.720.620.780.730.590.54
PAT to CFO Conversion(x)N/AN/A3.812.263.643.27
Working Capital Days
Receivable Days363827242424
Inventory Days232416121214
Payable Days340420357306312322

Dr. Agarwals Health Care Ltd Stock News

Dr. Agarwals Health Care Ltd FAQs

The current trading price of Dr. Agarwals Health on 05-Dec-2025 14:26 is ₹499.0.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2025 the market cap of Dr. Agarwals Health stood at ₹15,911.3.
The latest P/E ratio of Dr. Agarwals Health as of 04-Dec-2025 is 325.2.
The latest P/B ratio of Dr. Agarwals Health as of 04-Dec-2025 is 8.14.
The 52-week high of Dr. Agarwals Health is ₹567.8 and the 52-week low is ₹327.4.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Dr. Agarwals Health is ₹1,160 ( Cr.) .

About Dr. Agarwals Health Care Ltd

Dr. Agarwal's Health Care Limited was incorporated at Chennai, Tamil Nadu as a public limited company under the Companies Act, 1956, pursuant to the certificate of incorporation dated April 19, 2010, issued by the RoC and commenced operations pursuant to the certificate for commencement of business dated May 29, 2010, issued by the RoC.

Dr. Agarwal's Health Care provides a comprehensive range of eye care services, including cataract, refractive and other surgeries; consultations, diagnoses and non-surgical treatments; and sell opticals, contact lenses and accessories, and eye care related pharmaceutical products. The company had a market share of around 25% of the total eye care service chain market in India during the Financial Year 2024. The company categorizes its Facilities as Primary Facilities [which are non-surgical eye care facilities); Secondary Facilities (which are surgical Facilities); and Tertiary Facilities (which are super-specialty surgical Facilities and include three centres of excellence (COEs)], depending upon the nature of services provided. The company’s business operations are structured as a “hub and spoke” model, which enables it to build a scalable and accessible platform for the continued growth of its business. 

The company’s Primary Facilities provide initial eye care diagnosis and clinical investigation services. The Secondary Facilities at its spokes provide select services including cataract surgeries and clinical investigations while its Tertiary Facilities have super-specialty surgical capabilities including retinal, corneal, and refractive surgeries. The company’s COEs, in addition to being Tertiary Facilities, also offer academic programs in ophthalmology and provide continuous training for its doctors, optometrists, and counsellors, among others. Its integrated hub and spoke model enable deeper geographic penetration, allowing greater accessibility to patients while driving efficiency of critical resources across the network. 

Business area of the company

The company and its subsidiaries/associate are primarily engaged in running, owning and managing eye care hospitals, opticals, pharmacies, etc.

Awards and accreditation

  • 2023: AHCL was awarded as ‘One of the Best Healthcare Brands - 2023’ at The Economic Times Best Healthcare Brands 2023.
  • 2024: ‘Best Employer 2024-2025 - Tamil Nadu’ at the 19th Employer Branding Awards.
  • 2022: AHCL was awarded ‘E4M Pride of India Brands’ at the Best of Bharat Awards 2022.
  • 2022: AHCL was awarded the ‘Best Eye Hospital’ at the Pulse Healthcare Awards, Tamil Nadu.
  • 2023: AHCL was ranked as ‘India’s Most Trusted Eye Hospitals category’ in the Trust Research Advisory’s Brand Trust Report, India Study 2023.
  • 2024:  AHCL was awarded the Bronze award for ‘Digital Initiative for Patient Education’ award at the Smart Hospitals and Diagnostic Awards, 2024.
  • 2024: AHCL was awarded the ‘Best Use of TV in Healthcare - Gold’ and ‘Best Use of Print in Healthcare - Silver’ awards at the annual e4m Indian Marketing Awards, 2024 - South.

History and milestones

  • 2010: Incorporation of the company. 
  • 2010: Entry into the Telangana (formerly a part of Andhra Pradesh) and Karnataka markets by entering into lease agreements for setting up eye clinics.
  • 2011: Investment by EILSF SPV 3 in the company. 
  • 2012: Entry into the Africa market by entering into an agreement with Dr, Amelia Buque to jointly promote eye hospitals and other health care related services in Mozambique.
  • 2017: Entry into the Maharashtra market through the acquisition of hospital facilities in Maharashtra.
  • 2019: Investment by Claymore Investments (Mauritius), an indirect wholly owned subsidiary of Temasek Holdings (Private) Limited and Value Growth Investment Holdings Pte. Ltd in the company through subscription of equity shares. 
  • 2019: Subscription of NCDs by British International Investment (formerly known as CDC Group PLC) in the company.
  • 2021: The Company launched its 100th eye care facility. 
  • 2022: Investment by TPG Capital’s Hyperion Investments Pte. Ltd. and Arvon Investments Pte. Ltd., an indirect wholly owned subsidiary of Temasek Holdings (Private) Limited in the Company through subscription of equity shares. 
  • 2022: Entry into the Jammu market through the acquisition of Dr. Sood eye care practices from Dr. Rohan and Raj Deep Sood. 
  • 2022: Strengthened presence in the Gujarat market through acquisition of the eye care business from Prizma Eyecare LLP, Dr. Sanjay Vallabhai Savani and Dr. Ashish P. Gusani
  • 2023: Strengthened presence in the Punjab market through the acquisition of Punjab Eye Hospital from Dr. Gurpal Singh.
  • 2024: Entry in the Uttar Pradesh market through the acquisition of an eye care business in Varanasi. Expanded its` presence in Punjab market by acquisition of Dr Thind Eye Care Private Limited.

To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×